The DOI matches its Crossref record.
High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis
Abstract
BACKGROUND: Syndecan‐1 is a transmembrane heparan sulphate proteoglycan that is involved in cell–cell adhesion, organization of cell–matrix adhesion, and regulation of growth factor signaling. METHODS: Specimens from 254 consecutive breast carcinoma (BC) cases (110 N0, 144 N1/2) with long‐term follow‐up (median, 95 months) were immunostained for syndecan‐1, estrogen receptor (ER), progesterone receptor (PgR), and p53; in 154 cases, c‐erbB‐2 status was known. Syndecan‐1 mRNA and protein expression also were evaluated in 20 breast tissue samples (10 normal and tumor pairs). RESULTS: Syndecan‐1 was expressed at high levels in 106 (42%) BCs; syndecan‐1 up‐regulation was confirmed by reverse transcriptase–polymerase chain reaction (RT‐PCR) studies. High syndecan‐1 expression was associated with high histologic grade, large tumor size, high mitotic count, c‐erbB‐2 overexpression, and ER and PgR negative status. At univariate survival analysis syndecan overexpression was related to poor prognosis (P < 0.01 for both overall survival (OS) and disease‐free survival). Bivariate survival analysis showed an additive adverse effect for syndecan‐1 and c‐erbB‐2 overexpression. At multivariate analysis, syndecan‐1 overexpression was independently associated with poor OS (hazard ratio [HR], 1.71; 95% confidence interval [CI], 1.08–2.69). High syndecan‐1 expression also was of independent prognostic value for OS in the group of 102 ER‐negative patients (HR, 2.42; 95% CI, 1.21–4.82). Stratifying patients on the basis of the type of adjuvant therapy given, high syndecan‐1 expression was associated with a higher risk of death only in patients treated with the cyclophosphamide‐methotrexate‐fluorouracil regimen (HR, 1.9; P = 0.09); at multivariate analysis for OS, this association proved to be of independent statistical significance (P = 0.03; HR, 2.15). CONCLUSIONS: Syndecan‐1 is expressed at high levels in a significant percentage of breast carcinomas and is related to an aggressive phenotype and poor clinical behavior. Cancer 2003;98:474–83. © 2003 American Cancer Society. DOI 10.1002/cncr.11515
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Proteoglycans in cancer biology, tumour microenvironment and angiogenesis
Iozzo, R. V., & Sanderson, R. D. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01236.x · Cited by 569
The extracellular matrix in breast cancer
Insua-Rodríguez, J., & Oskarsson, T. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.017 · Cited by 470
Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N., & Karamanos, N. K. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2010.07800.x · Cited by 403
Transmembrane Signaling Proteoglycans
Couchman, J. R. (2010) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-100109-104126 · Cited by 403
Metadata
- Authors
- Barbareschi, M., Maisonneuve, P., Aldovini, D., Cangi, M. G., Pecciarini, L., Angelo Mauri, F., Veronese, S., Caffo, O., Lucenti, A., Palma, P. D., Galligioni, E., & Doglioni, C.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-06-13
- Volume
- 98
- Issue
- 3
- Pages
- 474-483
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2021467798
- Cited by
- 241
- References
- 0
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. https://app.cochat.ai/papers/10.1002/cncr.11515
- The paper
- Barbareschi, M., Maisonneuve, P., Aldovini, D., Cangi, M. G., Pecciarini, L., Angelo Mauri, F., Veronese, S., Caffo, O., Lucenti, A., Palma, P. D., Galligioni, E., & Doglioni, C. (2003). High syndecan‐1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer. https://doi.org/10.1002/cncr.11515
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.